Juncell Therapeutics is focused on developing personalized TIL therapies for the treatment of solid tumors. The company says it has systematically optimized its cell culture processes and established an independent quality management system aligned with GMP specifications. Juncell reports achieving internationally advanced levels on metrics such as culture success rate, cell count, and cytotoxic activity. Clinically, its TIL therapy has shown strong efficacy in several patients with advanced solid tumors even without intensive lymphodepletion and IL-2 injection. The company also reports improved safety because patients have been treated in general wards. Juncell intends to focus on the TIL field and accelerate clinical development across multiple TIL pipelines, supported by recent financing.

Total raised

$1M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2022